Copyright © 2018 Claristock. All Right Reserved
Total Mark
86
Above 70 is preferred
Stock Analysis
| Growth Potential | 94 | |
|---|---|---|
| Profitability | 88 | |
| Financial Strength | 83 | |
| Q3 2020 Result | 42 | |
| Q2 2020 Result | 100 | |
| Result 2019 | 83 |
Growth Estimate
| 21 Estimate | 22 Estimate | |
|---|---|---|
| Revenue Growth (%) | 17.3 | 24.4 |
| EPS Growth (%) | 63.8 | 38.8 |
| ROE (%) | 35.3 | 34.2 |
| P/E (times) | ... | ... |
Market Analysis
| Market Sentiment | 43 | |
|---|---|---|
| Relative Valuation | 98 | |
| Being a Value Stock | 59 | |
| Absolute Valuation | NA |
For more detailed information about Neurocrine Biosciences Inc, please go to Yahoo Finance